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Although psychotherapy and antidepressant medication are efficacious in the treatment of depressive and anxiety disorders, it is not known
whether they are equally efficacious for all types of disorders, and whether all types of psychotherapy and antidepressants are equally effica-
cious for each disorder. We conducted a meta-analysis of studies in which psychotherapy and antidepressant medication were directly com-
pared in the treatment of depressive and anxiety disorders. Systematic searches in bibliographical databases resulted in 67 randomized trials,
including 5,993 patients that met inclusion criteria, 40 studies focusing on depressive disorders and 27 focusing on anxiety disorders. The
overall effect size indicating the difference between psychotherapy and pharmacotherapy after treatment in all disorders was g50.02 (95%
CI: 20.07 to 0.10), which was not statistically significant. Pharmacotherapy was significantly more efficacious than psychotherapy in dysthy-
mia (g50.30), and psychotherapy was significantly more efficacious than pharmacotherapy in obsessive-compulsive disorder (g50.64). Fur-
thermore, pharmacotherapy was significantly more efficacious than non-directive counseling (g50.33), and psychotherapy was significantly
more efficacious than pharmacotherapy with tricyclic antidepressants (g50.21). These results remained significant when we controlled for
other characteristics of the studies in multivariate meta-regression analysis, except for the differential effects in dysthymia, which were no
longer statistically significant.
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Depressive and anxiety disorders are highly prevalent
(1,2) and associated with high levels of service use, a consid-
erable disease burden (3), substantial economic costs (4–6),
and a significant loss of quality of life for patients and their
relatives (7,8). Several efficacious treatments for depressive
and anxiety disorders are available, including different
forms of psychotherapy and antidepressant medication (9–
11). Although both types of treatment have been found to be
efficacious, it is not known whether they are equally effica-
cious for all types of depressive and anxiety disorders. There
is evidence from meta-analyses of studies comparing psy-
chotherapy and pharmacotherapy directly that they are
about equally efficacious in depression (12) and generalized
anxiety disorder (GAD) (13). It is not clear whether this is
true for all depressive and anxiety disorders. For example,
for obsessive-compulsive disorder (OCD) and social anxiety
disorder (SAD), no meta-analyses of direct comparisons
between psychotherapy and pharmacotherapy have been
conducted yet, even though a considerable number of such
comparative trials have been carried out.
Furthermore, it remains unclear whether all types of psy-
chotherapy and all types of antidepressant medications have
comparable effects. In one previous meta-analysis, we found
that treatment with selective serotonin reuptake inhibitors
(SSRIs) was somewhat more effective than treatment with
psychotherapy (12), whereas tricyclic antidepressants (TCAs)
and psychotherapy were equally effective. A re-analysis of
those data, however, showed that there were no significant
differences between psychotherapy and SSRIs after adjusting
for differential drop-out from both treatments. Another meta-
analysis confirmed that psychotherapy and SSRIs were
equally effective, when only bona fide psychotherapies were
included (14).
It is also possible that there are differences between differ-
ent forms of psychotherapy. There are some indications from
meta-analytic research that interpersonal psychotherapy
(IPT) may be somewhat more efficacious than other psycho-
therapies in the treatment of depression (15,16), although
this is not confirmed in all meta-analyses (17). There are also
some indications that psychodynamic psychotherapy (18)
and non-directive supportive counselling (19) may be some-
what less efficacious than other psychotherapies. Given these
potential differences between psychotherapies, it is conceiva-
ble that the differential effects of psychotherapy and pharma-
cotherapy may depend on the type of psychotherapy. Earlier
meta-analyses may have failed to detect these differential
effects because of the small number of included studies and
the resulting lack of statistical power.
We report here the results of an overall meta-analysis of
the studies in which psychotherapy and antidepressant
medication for depressive and anxiety disorders were
directly compared with each other.
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METHODS
Identification and selection of studies
Several strategies were used to identify relevant studies.
We searched four major bibliographical databases (PubMed,
PsycInfo, EMBASE and the Cochrane database of random-
ized trials) by combining terms indicative of each of the dis-
orders with terms indicative of psychological treatment
(both MeSH terms and text words) and randomized con-
trolled trials. We also checked the references of 116 earlier
meta-analyses of psychological treatments for the included
disorders. Details of the searches and exact search strings are
given in Figure 1.
We included randomized trials in which the effects of a
psychological treatment were directly compared with the
effects of antidepressant medication in adults with depres-
sive disorder, panic disorder with or without agoraphobia,
GAD, SAD, OCD, or post-traumatic stress disorder (PTSD).
Only studies in which subjects met diagnostic criteria for the
disorder according to a structured diagnostic interview –
such as the Structured Clinical Interview for DSM-IV
(SCID), the Composite International Diagnostic Interview
(CIDI) or the Mini International Neuropsychiatric Inter-
view (MINI) – were included. Comorbid mental or somatic
disorders were not used as an exclusion criterion. Studies on
inpatients, adolescents and children (below 18 years of age)
were excluded. We also excluded maintenance studies,
aimed at people who had already recovered or partly recov-
ered after an earlier treatment, and studies on other types of
medication, such as benzodiazepines for anxiety disorders.
Studies in English, German, Spanish and Dutch were con-
sidered for inclusion.
Quality assessment and data extraction
We evaluated the quality of included studies using the
Cochrane Collaboration “risk of bias” assessment tool (20).
This tool assesses possible sources of bias in randomized tri-
als, including the adequate generation of allocation sequence,
the concealment of allocation to conditions, the prevention
of knowledge of the allocated intervention (masking of asses-
sors), and dealing with incomplete outcome data (this was
rated as positive when intention-to-treat analyses were con-
ducted, meaning that all randomized patients were included
in the analyses). The assessment was conducted by two inde-
pendent researchers, and disagreements were solved through
discussion.
We also coded the participant characteristics (disorder,
recruitment method, target group); the type of antidepres-
sant which was used (SSRI, TCA, monoamine oxidase in-
hibitor (MAOI), other or protocolized treatment including
several antidepressants); and the characteristics of the psy-
chotherapy (format, number of sessions, and type of psycho-
therapy). The types of psychotherapy we identified were
cognitive-behavioral therapy (CBT), IPT, problem-solving
therapy, non-directive supportive counselling, psychody-
namic psychotherapy, and others. Although CBTs used a
mix of different techniques, we clustered them together in
one group. We rated a therapy as CBT when it included cog-
nitive restructuring or a behavioral approach (such as expo-
sure and response prevention). When a therapy used a mix
of CBT and IPT, we rated it as “other”, along with other ther-
apeutic approaches.
Meta-analyses
For each comparison between a psychotherapy and a
pharmacotherapy, the effect size indicating the difference
between the two groups at post-test (Hedges’ g) was eval-
uated. Effect sizes were calculated by subtracting (at post-
test) the average score of the psychotherapy group from the
average score of the pharmacotherapy group, and dividing
the result by the pooled standard deviation. Because some
studies had relatively small sample sizes, we corrected the
effect size for small sample bias (21).
In the calculations of effect sizes in studies of patients
with depressive disorders, we used only those instruments
that explicitly measured symptoms of depression. In studies
examining anxiety disorders, we only used instruments that
explicitly measured symptoms of anxiety. If more than one
measure was used, the mean of the effect sizes was calcu-
lated, so that each study provided only one effect size. If
means and standard deviations were not reported, we used
the procedures of the Comprehensive Meta-Analysis soft-
ware (version 2.2.021) to calculate the effect size using di-
chotomous outcomes; and if these were not available ei-
ther, we used other statistics (such a t value or p value). To
calculate pooled mean effect sizes, we also used the Com-
prehensive Meta-Analysis software. Because we expected
considerable heterogeneity among the studies, we employed
a random effects pooling model in all analyses.
We only examined the differential effects at post-test
and did not look at the longer-term effects. The types of
outcomes reported at follow-up and the follow-up periods
differed widely between studies. Furthermore, some stud-
ies reported only naturalistic outcomes, while others
delivered booster sessions and maintenance treatments
during the whole follow-up period or part of it. Because of
these large differences, we decided it was not meaningful
to pool the results of these outcomes.
As a test of homogeneity of effect sizes, we calculated
the I2 statistic. A value of 0% indicates no observed hetero-
geneity, and higher values indicate increasing heterogene-
ity, with 25% as low, 50% as moderate, and 75% as high
heterogeneity (22). We calculated 95% confidence intervals
around I2 (23) using the non-central chi-squared-based
approach within the Heterogi module for Stata (24).
We conducted subgroup analyses according to the mixed
effects model, in which studies within subgroups are pooled
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with the random effects model, while tests for significant dif-
ferences between subgroups are conducted with the fixed
effects model. For continuous variables, we used meta-
regression analyses to test whether there was a significant
relationship between the continuous variable and the effect
size, as indicated by a Z value and an associated p value.
We tested for publication bias by inspecting the funnel
plot on primary outcome measures and by Duval and
Tweedie’s trim and fill procedure (25), which yields an
estimate of the effect size after the publication bias has
been taken into account. We also conducted Egger’s test
of the intercept to quantify the bias captured by the funnel
plot and test whether it was significant.
Multivariate meta-regression analyses were conducted
with the effect size as the dependent variable. To decide which
variables should be entered as predictors in the regression
model, we first defined a reference group within each category
of variables. To avoid collinearity among the predictors of the
regression model, we first examined whether high correla-
tions were found among the variables that could be entered
into the model. Next, we calculated the correlations between
all predictors (except the reference variables). Because no cor-
relations were higher than r50.60, all predictors could be
entered in the regression models. Multivariate regression anal-
yses were conducted in STATA MP, version 11 for Mac.
RESULTS
Selection and inclusion of studies
After examining a total of 21,729 abstracts (14,903 after
removal of duplicates), we retrieved 2,278 full-text papers for
Figure 1 Selection and inclusion of studies
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Table 1 Selected characteristics of included studies
Study Disorder Psychotherapy Medication Quality* Country
Bakhshani et al (26) GAD CBT (n57) TCA (n57) 222 1 Iran
Bakker et al (27) PAN CBT (n535) SSRI (n532) 222 1 Europe
TCA (n532)
Barber et al (28) MDD DYN (n551) Mixed/other (n555) 221 1 USA
Barlow et al (29) PAN CBT (n565) TCA (n583) 221 1 USA
Barrett et al (30) Mood PST (n580) SSRI (n580) 111 1 USA
Bedi et al (31) MDD Counseling (n539) Mixed/other (n544) 112 2 Europe
Black et al (32) PAN CBT (n525) SSRI (n525) 222 2 USA
Blackburn & Moore (33) MDD CBT Mixed/other 222 1 Europe
Blanco et al (34) SAD CBT (n532) MAOI (n535) 111 1 USA
Blomhoff et al (35) SAD BT (n598) SSRI (n595) 111 1 Europe
Browne et al (36) DYS IPT (n5122) SSRI (n5117) 111 2 Canada
Clark et al (37) PAN CBT (n516) TCA (n516) 221 2 Europe
Dannon et al (38) PAN CBT (n523) SSRI (n527) 222 2 Israel
David et al (39) MDD CBT (n556) SSRI (n557) 221 1 Europe
REBT (n557)
Davidson et al (40) SAD CBT (n542) SSRI (n539) 111 1 USA
Dekker et al (41) MDD DYN (n559) Mixed/other (n544) 221 2 Europe
Dunlop et al (42) MDD CBT (n541) SSRI (n539) 111 1 USA
Dunner et al (43) DYS CBT (n59) SSRI (n511) 221 2 USA
Elkin et al (44) MDD IPT (n561) TCA (n557) 111 1 USA
CBT (n559)
Faramarzi et al (45) MDD CBT (n529) SSRI (n530) 221 2 Iran
Finkenzeller et al (46) MDD IPT (n523) SSRI (n524) 121 1 Europe
Foa et al (47) OCD BT (n519) TCA (n527) 221 2 USA
Frank et al (48) MDD IPT (n5160) SSRI (n5158) 221 1 USA
Frommberger et al (49) PTSD CBT (n510) SSRI (n511) 222 2 Europe
Hegerl et al (50) Mood CBT (n552) SSRI (n576) 111 1 Europe
Heimberg et al (51) SAD CBT (n528) MAOI (n527) 221 1 USA
Counseling (n526)
Hendriks et al (52) PAN CBT (n520) SSRI (n517) 111 1 Europe
Hoexter et al (53) OCD CBT (n513) SSRI (n513) 121 2 Brazil
Hollon et al (54) MDD CBT (n525) TCA (n557) 221 1 USA
Jarrett et al (55) MDD CBT (n536) MAOI (n536) 111 1 USA
Keller et al (56) MDD CBASP (n5226) SNRI (n5220) 111 1 USA
Kolk et al (57) PTSD EMDR (n524) SSRI (n526) 221 1 USA
Koszycki et al (58) PAN CBT (n559) SSRI (n562) 111 1 Canada
Lesperance et al (59) MDD IPT (n567) SSRI (n575) 111 1 Canada
Loerch et al (60) PAN CBT (n514) MAOI (n516) 221 1 Europe
Markowitz et al (61) DYS IPT (n523) SSRI (n524) 221 1 USA
Counseling (n526)
Marshall et al (62) MDD CBT (n537) Mixed/other (n530) 222 2 Canada
IPT (n535)
Martin et al (63) MDD IPT (n513) SNRI (n515) 222 1 Europe
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further consideration. We excluded 2,211 of the retrieved
papers. The flow chart describing the inclusion process,
including the reasons for exclusion, is presented in Figure 1.
A total of 67 studies met the inclusion criteria for this meta-
analysis. Selected characteristics of the included studies (26–
92) are reported in Table 1.
Characteristics of included studies
In the 67 studies, a total of 5,993 patients participated
(3,142 in the psychotherapy and 2,851 in the pharmaco-
therapy conditions). Forty studies focused on depressive
Table 1 Selected characteristics of included studies (continued)
Study Disorder Psychotherapy Medication Quality* Country
McBride et al (64) MDD CBT (n521) Mixed/other (n521) 222 2 Canada
McKnight et al (65) MDD CBT TCA 222 2 USA
McLean & Hakstian (66) MDD DYN (n544) TCA (n549) 221 2 Canada
BT (n542)
Miranda et al (67) MDD CBT (n590) Mixed/other (n588) 111 1 USA
Mohr et al (68) MDD CBT (n520) SSRI (n515) 222 1 USA
Supp Ex (n519)
M€ortberg et al (69) SAD CBT ind (n532) Mixed/other (n533) 111 1 Europe
CBT grp (n535)
Murphy et al (70) MDD CBT (n522) TCA (n524) 112 1 USA
Murphy et al (71) MDD PST (n529) TCA (n527) 111 1 Europe
Mynors-Wallis et al (72) MDD PST gp (n539) SSRI (n536) 111 1 Europe
PST n (n541)
Nakatani et al (73) OCD BT (n510) SSRI (n510) 221 2 Japan
Nazari et al (74) OCD EMDR (n530) SSRI (n530) 221 2 Iran
Oosterbaan et al (75) SPH CBT (n528) MAOI (n527) 221 1 Europe
Prasko et al (76) SPH CBT (n522) MAOI (n520) 221 2 Europe
Ravindran et al (77) DYS CBT (n524) SSRI (n522) 111 2 Canada
Reynolds et al (78) MDD IPT (n516) TCA (n525) 221 1 USA
Rush et al (79) MDD CBT (n519) TCA (n522) 221 1 USA
Salminen et al (80) MDD DYN (n526) SSRI (n525) 222 1 Europe
Schulberg et al (81) MDD IPT (n593) TCA (n591) 2 21 1 USA
Scott & Freeman (82) MDD CBT (n529) TCA (n526) 111 1 Europe
Counseling (n529)
Shamsaei et al (83) MDD CBT (n540) SSRI (n540) 121 2 Iran
Shareh et al (84) OCD CBT (n56) SSRI (n56) 222 2 Iran
Sharp et al (85) PAN CBT (n529) SSRI (n529) 222 2 Europe
Sharp et al (86) Mood Counseling (n5112) Mixed/other (n5106) 111 1 Europe
Sousa et al (87) OCD CBT (n525) SSRI (n525) 221 2 Brazil
Spinhoven et al (88) PAN CBT (n520) SSRI (n519) 222 1 Europe
Thompson et al (89) MDD CBT (n536) TCA (n533) 222 1 USA
Van Apeldoorn et al (90) PAN CBT (n536) Mixed/other (n537) 111 1 Europe
Weissman et al (91) MDD IPT (n523) TCA (n520) 221 2 USA
Williams et al (92) Mood PST (n5113) SSRI (n5106) 111 1 USA
*A positive or negative sign is given for four quality criteria: allocation sequence, concealment of allocation to conditions, blinding of assessors, and intention-to-
treat analysis
GAD – generalized anxiety disorder, PAN – panic disorder with or without agoraphobia, MDD – major depressive disorder, Mood – mixed mood disorder, SAD –
social anxiety disorder, DYS – dysthymic disorder, OCD – obsessive-compulsive disorder, PTSD – post-traumatic stress disorder, CBT – cognitive-behavioral ther-
apy, DYN – psychodynamic therapy, PST – problem-solving therapy, BT – behavior therapy, IPT – interpersonal psychotherapy, REBT – rational emotive behav-
ior therapy, CBASP – cognitive behavioral analysis system of psychotherapy, EMDR – eye movement desensitization and reprocessing, Supp Ex – supportive-ex-
pressive therapy, ind – individual format, grp – group format, gp – delivered by a general practitioner, n – delivered by a nurse, TCA – tricyclic antidepressant,
SSRI – selective serotonin reuptake inhibitor, MAOI – monoamine oxidase inhibitor, SNRI – serotonin-norepinephrine reuptake inhibitor
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Table 2 Comparative effects of psychotherapy and pharmacotherapy: subgroup analyses
N g 95% CI I2 95% CI p
All studies 78 0.02 20.07 to 0.10 62 52 to 70
Possible outliers removed 68 20.07 20.14 to 0.01 41 21 to 56
One effect size per study (highest) 67 0.06 20.03 to 0.15 62 51 to 71
One effect size per study (lowest) 67 0.03 20.07 to 0.12 62 51 to 71
Mood disorders
Any mood disorder 48 20.03 20.14 to 0.08 52 0 to 47 0.01
Major depression 39 0.02 20.10 to 0.13 46 22 to 63
Dysthymia 5 20.30 20.60 to 20.00 55 0 to 83
Mixed mood disorders 4 20.14 20.45 to 0.17 64 0 to 88
Anxiety disorders
Any anxiety disorder 30 0.10 20.05 to 0.25 71 59 to 80
Panic disorder 12 0.00 20.28 to 0.28 62 28 to 79
SAD 9 20.03 20.34 to 0.28 74 50 to 87
OCD 6 0.64 0.20 to 1.08 72 36 to 88
Other 3 0.24 20.39 to 0.86 0 0 to 90
Psychotherapy type
Cognitive-behavioral therapy 49 0.09 20.03 to 0.20 60 46 to 71 0.12
Interpersonal psychotherapy 11 20.09 20.31to 0.14 65 33 to 82
Problem-solving therapy 5 20.04 20.36 to 0.27 0 0 to 79
Counseling 6 20.33 20.64 to 20.02 69 27 to 87
Other 7 0.07 20.21 to 0.34 67 27 to 85
Treatment format
Individual 62 0.02 20.08 to 0.12 61 48 to 70 0.89
Group 14 0.03 20.18 to 0.25 71 50 to 83
Pharmacotherapy
SSRI 37 0.01 20.12 to 0.13 58 40 to 71 0.02
TCA 20 0.21 0.04 to 0.39 52 19 to 71
MAOI 7 20.05 20.34 to 0.25 83 65 to 91
Mixed/protocol/other 14 20.19 20.37 to 0.00 49 5 to 72
Recruitment
Only clinical samples 36 0.07 20.06 to 0.20 55 34 to 69 0.52
Also community recruitment 35 20.03 20.16 to 0.10 65 50 to 76
Other recruitment method 7 20.04 20.34 to 0.25 76 49 to 89
Country
USA 31 20.07 20.21 to 0.07 52 28 to 68 0.17
Europe 29 0.03 20.11 to 0.17 56 34 to 71
Other 18 0.15 20.04 to 0.34 76 62 to 85
Quality
Score 0–1 31 0.10 20.06 to 0.25 69 56 to 79 0.44
Score 2–3 23 20.03 20.19 to 0.13 65 46 to 78
Score 4 24 20.02 20.17 to 0.12 38 0 to 62
All subgroup analyses were conducted with the random effects model; a positive effect size indicates superior effects of psychotherapy; the p values indicate
whether the effect sizes in the subgroups differ significantly from each other; significant values are highlighted in bold
SAD – social anxiety disorder, OCD – obsessive-compulsive disorder, SSRI – selective serotonin reuptake inhibitor, TCA – tricyclic antidepressant, MAOI – mon-
oamine oxidase inhibitor
Figure 2 Differential effects of psychotherapy and pharmacotherapy (Hedges’ g)
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disorders (32 on major depressive disorder, four on dysthy-
mia, and four on mixed mood disorders) and 27 on anxiety
disorders (11 on panic disorder with or without agorapho-
bia, six on OCD, seven on SAD, two on PTSD, and one on
GAD). Many studies (n532) recruited patients exclusively
from clinical samples, and most (n556) were aimed at
adults in general instead of a more specific population
(such as older adults or patients with a comorbid somatic
disorder). Most psychotherapies (49 of the 78 that were
examined in these studies) were characterized as CBT; 11
studies examined IPT, five problem-solving therapy, six
non-directive counseling, four psychodynamic therapies,
and the remaining three other therapies. Most therapies
(n562) used an individual treatment format, and the num-
ber of treatment sessions ranged from 6 to 20, with most
therapies (n545) having between 12 and 18 sessions. The
antidepressants that were examined in the studies included
SSRIs (n537), TCAs (n520), SNRIs (n52), MAOIs (n57),
and treatment protocols with different types of antidepres-
sant medication (n512). Most studies were conducted in
the United States (n527) or in Europe (n523).
Quality assessment
The quality of the studies varied. Twenty-seven studies
reported an adequate sequence generation, while the other 40
did not. Twenty-four studies reported allocation to conditions
by an independent (third) party. Forty-nine studies reported
blinding of outcome assessors or used only self-report out-
comes, whereas 18 did not report blinding. Forty-two studies
conducted intention-to-treat analyses (a post-treatment score
was analyzed for every patient even if the last observation
Table 3 Standardized regression coefficients of characteristics of psychotherapy and pharmacotherapy studies
Full model Parsimonious model
Coef. 95% CI p Coef. 95% CI p
Disorder
MDD Ref.
Dysthymia 20.01 20.46 to 0.43
Other mood disorder 0.02 20.42 to 0.45
Panic disorder 20.10 0.42 to 0.21
SAD 0.12 20.28 to 0.53
OCD 0.52 0.01 to 1.03 <0.05 0.76 0.36 to 1.15 <0.001
Other anxiety disorder 0.32 20.30 to 0.95
Recruitment from clinical samples only 0.05 20.17 to 0.26
Adults in general vs. specific target group 20.41 20.70 to-0.13 <0.01 20.27 20.50 to - 0.05 <0.05
Psychotherapy
CBT Ref.
ITP 20.16 20.45 to 0.12
Counseling 20.51 20.92 to 20.19 <0.05 20.41 20.72 to 20.09 <0.05
Other therapy 20.03 20.39 to 0.33
Pharmacotherapy
SSRI Ref.
TCA 0.32 0.06 to 0.58 <0.05 0.31 0.11 to 0.50 <0.01
MAOI 0.07 20.34 to 0.48
Other 20.23 20.51 to 0.05
Individual psychotherapy format 0.01 20.27 to 0.28
Number of psychotherapy sessions 0.01 20.02 to 0.04
Quality of study 0.00 20.07 to 0.08
Country
USA Ref.
Europe 0.26 0.03 to 0.49 <0.05 0.18 0.00 to 0.36 <0.05
Other 20.00 20.31 to 0.31
Constant 0.31 20.29 to 0.91 0.09 20.12 to 0.29
MDD – major depressive disorder, SAD – social anxiety disorder, OCD – obsessive-compulsive disorder, CBT – cognitive-behavioral therapy, ITP – interpersonal
psychotherapy, SSRI – selective serotonin reuptake inhibitor, TCA – tricyclic antidepressant, MAOI – monoamine oxidase inhibitor
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prior to attrition had to be carried forward or that score was
estimated from earlier response trajectories). Twenty studies
met all four quality criteria, four studies met three criteria, and
the remaining 43 studies met two criteria or less.
Comparative effects of psychotherapy and
pharmacotherapy
The overall mean effect size indicating the difference
between psychotherapy and pharmacotherapy at post-test
for all 78 comparisons was 0.02 (95% CI: 20.07 to 0.10;
Table 2), in favor of psychotherapy, but not significantly
different from zero. Heterogeneity was moderate to high
(I2562; 95% CI: 52 to 70). The results of these overall
analyses are presented in Figure 2.
Removing possible outliers (in which the 95% CI of the
effect size did not overlap with the 95% CI of the pooled
effect size) resulted in a small, non-significant effect size
in favor of pharmacotherapy and somewhat lower hetero-
geneity (I2541; low to moderate).
In this meta-analysis, we included ten studies in which
two psychological treatments were compared with the same
pharmacotherapy group, as well as one study in which one
psychological treatment was compared with two different
types of antidepressant medication. This means that multi-
ple comparisons from these studies, not independent from
each other, were included in the same analysis, which may
have resulted in an artificial reduction of heterogeneity and
may have affected the pooled effect size. We examined the
possible effects of this by conducting an analysis in which
we included only one effect size per study. First, we included
only the comparison with the largest effect size from these
studies and then we conducted another analysis in which
we included only the smallest effect size. As can be seen
from Table 2, the resulting effect sizes as well as the levels of
heterogeneity were comparable with the overall analyses.
We found no indications for publication bias. The effect
size did not change after adjusting for publication bias
according to Duval and Tweedie’s trim and fill procedure,
and according to this procedure no missing study had to
be imputed.
Univariate moderator analyses
We examined whether there were significant differences
between psychotherapy and pharmacotherapy in specific
subgroups of studies. The results of these subgroup analyses
are presented in Table 2. We found that the effect size was
significantly associated with the type of disorder (p<0.01).
More specifically, we found that pharmacotherapy was more
efficacious than psychotherapy in dysthymia (differential
effect size: g520.30; 95% CI: 20.60 to 20.00; I2555; 95%
CI: 0 to 83). By contrast, psychotherapy was more efficacious
than pharmacotherapy in OCD (differential effect size:
g50.64; 95% CI: 0.20 to 1.08; I2572; 95% CI: 36 to 88).
We also found that type of pharmacotherapy was
significantly associated with the differential effect size
(p<0.05). Treatment with a TCA was significantly less effi-
cacious than psychotherapy (g50.21; 95% CI: 0.04 to
0.39; I2552; 95% CI: 19 to 71), while there was no signifi-
cant difference between other types of pharmacotherapy
and psychotherapy. Furthermore, we found that treatment
with non-directive supportive counseling was less effica-
cious than pharmacotherapy (g520.33; 95% CI: 20.64 to
20.02; I2569; 95% CI: 27 to 87).
We did not find that the effect size was associated with
the treatment format in psychotherapy, recruitment method
of patients, country where the study was conducted, or the
quality of the study.
Multivariate meta-regression analyses
Because we found several important moderators of out-
come in the univariate moderator analyses, we decided to
conduct a multivariate meta-regression analysis in which
we entered the relevant predictors simultaneously. The
results of these analyses are presented in Table 3. The effects
of psychotherapy were still significantly higher than those of
pharmacotherapy in studies on OCD, even after adjusting
for other characteristics of the included studies. We also
found that non-directive supportive counseling was still sig-
nificantly less efficacious than pharmacotherapy, and TCAs
remained significantly less efficacious than psychotherapy.
In dysthymia, psychotherapy and pharmacotherapy did no
longer differ significantly from each other.
In the multivariate meta-regression analysis, the effects of
two predictors became significant: studies in Europe had a
higher pooled effect size (indicating superior effects of psy-
chotherapy) than studies in other parts of the world, and
pharmacotherapy was significantly more efficacious in stud-
ies among specific target groups (such as older adults and
patients who also had a general medical disorder) than in
those among adults in general.
We also conducted a (manual) back-step meta-regres-
sion analysis. In this analysis, we dropped the least signifi-
cant variable in each step, until only significant predictors
(p<0.05) were retained in the model (Table 3). In this par-
simonious model, we found that the same predictors were
significant as in the full meta-regression model.
DISCUSSION
In this meta-analysis, we found that the differences
in effects between psychotherapy and antidepressant medi-
cation were small to non-existent for major depression,
panic disorder and SAD. We also found evidence that
pharmacotherapy was significantly more efficacious in dys-
thymia, and that psychotherapy was significantly more effi-
cacious in OCD. Furthermore, pharmacotherapy was sig-
nificantly more efficacious than non-directive counseling,
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and psychotherapy was significantly more efficacious than
pharmacotherapy with TCAs. These associations remained
significant when we controlled for other characteristics of
the studies in multivariate meta-regression analysis, except
for the differential effects in dysthymia, which were no longer
significant. In these multivariate meta-regression analyses,
we also found that psychotherapy was more efficacious in
studies from Europe compared with those from other coun-
tries, and that pharmacotherapy was significantly more effi-
cacious in studies among specific target groups than in those
among adults in general.
The present results indicate that different kinds of antide-
pressants and psychotherapies have varying degrees of efficacy
in treating depression and anxiety disorders. TCAs and non-
directive counseling seemed to be less efficacious than the
other treatments, although we found in an earlier meta-analy-
sis that the lower effects of non-directive counseling may be
caused in part by researcher allegiance (93). The finding that
psychotherapy is less efficacious than pharmacotherapy in
dysthymia is in line with earlier meta-analytic research (94).
However, the number of studies is small and the difference
was no longer statistically significant after adjusting for quality
and other study characteristics. As such, the finding is not very
stable and more research is needed to examine this issue.
In OCD, the outcomes are rather straightforward in that
psychotherapy is clearly more efficacious than antidepres-
sants, even adjusting for quality and other characteristics of
the studies. This is the first meta-analysis to show that psy-
chotherapy is more efficacious than pharmacotherapy. This
finding is also important from a clinical perspective, because
OCD is often regarded as the most severe anxiety disorder.
One of the strengths of this study is the broad range of dis-
orders and treatments we included. But the study also has
some limitations. First, for several disorders insufficient
numbers of studies were available. We only had a few stud-
ies examining PTSD, GAD and dysthymia. Second, the qual-
ity of many of the included studies was not optimal. Third,
because of the many differences between the studies, we
only examined the differential effects of psychotherapy and
pharmacotherapy at post-test, and did not look at the long-
er-term effects. There are indications that psychotherapy
may have sustained effects over the longer-term, while anti-
depressants do not have strong effects when the patients
stop taking them (95). Fourth, we only considered the effects
of treatments on the disorders they were designed to
address. Finally, while it is well known that pharmacothera-
pies have several side effects, which are often reported in the
studies, the idea that psychotherapies can have negative
effects has only recently been recognized (96), and these
negative effects are typically not reported in the studies. It
was, therefore, not possible to compare psychotherapies and
pharmacotherapies in terms of negative effects.
Despite the limitations, we can conclude that pharmaco-
therapy and psychotherapy have comparable effects in sev-
eral depressive and anxiety disorders, but this is not true for
all disorders, especially not for OCD and possibly dysthymia.
Furthermore, most psychotherapies and pharmacotherapies
are equally efficacious, but this again is not true for all treat-
ments, especially for TCAs and non-directive supportive
counseling. Finally, while treatments may be equal in effects,
they may not be equal in terms of patient preferences and
costs, which deserve further investigations across disorders.
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